Enhanced screening and management for advanced HIV patients, incorporating Cryptococcal disease prevention, TB treatment and same day/rapid ART Initiation: a stepped wedge cluster randomised trial
Not Applicable
Recruiting
- Conditions
- HIV/AIDSTuberculosisCryptococcal disease
- Registration Number
- PACTR201901672543518
- Lead Sponsor
- Medecins Sans Frontieres OCB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 900
Inclusion Criteria
1) Patients aged 18 years and older
2) New HIV positive patients with CD4< 200 cell counts/µl
3) Immunosuppressed on ART treatment patients with VL>1000 copies/ml and CD4<200 cell counts/ µl
4) Patients returning after defaulting for more than 3 months with a CD4<200
5) Written, informed consent for data collection (control and intervention arms)
6) Written, informed consent for participation in intervention (intervention arm)
Exclusion Criteria
1) Patients requiring hospitalization
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cryptococcal disease prevention in advanced HIV patients with ART initiation?
How does rapid ART initiation compare to standard-of-care in preventing opportunistic infections in HIV/TB co-infected patients?
Which biomarkers are associated with treatment response in HIV patients with cryptococcal antigenemia and TB co-infection?
What are the potential adverse events of same-day ART initiation in advanced HIV patients with TB and cryptococcal disease?
What combination therapies are being explored for HIV/TB/crypto co-infections beyond the PACTR201901672543518 trial?